Guide of Coming Off-patent Agrochemical Active Ingredients

Report edition: 2012 edition(1)
Finished time: Nov. 2012
Document type: PDF
Total pages : 107
Language version: English
Published by CCM

Single user license: USD 1,800
Corporate license: USD 4,500

All the prices on this website exclude VAT.

CCM_sample_Guide of Coming Off-patent Agrochemical Active Ingredients

Introduction
Main contents
List of tables
List of figures

Description:

In the global pesticide market, generic pestcides accounted for 75% in the terms of registration quantity. During the time from Nov. 2012 to Dec. 2016, patents of 35 pesticide varieties will be expired. And By 2023, 166 pesticide-related patents will be expired all ovet the world (among which only 30 varieties belong to China), and it is expected that an added market value reaching USD11 billion will be created.

In this report, CCM focuses on the patent products including basic information, synsthesis route, application, physical & safety data, patent situation and registration situation.

Through this report, you can:

- Gain an overview of general situation of the coming off-patent products;

- Know the registration situtaion of the hot products of agricultural giants in the main agricultural countries;

- It is a good guide for other pesticide companies who are interested in the commercial development of these coming off-patent products.

Main contents:

(The price of report chapters below is for single user license, please contact us if you want to update to corporate license.)

No.	Content	Page	Price
	Methodology and scope	1	$ 18
1	Profiles of coming off-patent herbicides	3	$ 630
1-1	Benzobicyclon	3	$ 72
1-2	Dimethenamid-P	4	$ 72
1-3	Fentrazamide	7	$ 72
1-4	Foramsulfuron	9	$ 90
1-5	Mesosulfuron-methyl	13	$ 90
1-6	Monosulfuron	16	$ 54
1-7	Oxaziclomefone	17	$ 72
1-8	Pyribenzoxim	19	$ 72
2	Profiles of coming off-patent insecticides	22	$ 630
2-1	Bifenazate	22	$ 72
2-2	Diflovidazin	26	$ 72
2-3	Dinotefuran	28	$ 90
2-4	Flonicamid	30	$ 72
2-5	Metaflumizone	33	$ 54
2-6	Methoxyfenozide	35	$ 72
2-7	Profurite-aminium	38	$ 72
2-8	Pyridalyl	40	$ 72
2-9	Spirodiclofen	42	$ 72
2-10	Thiamethoxam	44	$ 126
2-11	Xiaochongthion	53	$ 54
3	Profiles of coming off-patent fungicides	55	$ 720
3-1	Benthiavalicarb-isopropyl	55	$ 54
3-2	Boscalid	57	$ 90
3-3	Cyflufenamid	61	$ 54
3-4	Ethaboxam	63	$ 54
3-5	Flumorph	65	$ 54
3-6	Ningnanmycin	67	$ 36
3-7	Orysastrobin	69	$ 36
3-8	Penthiopyrad	71	$ 54
3-9	Proquinazid	73	$ 54
3-10	Prothioconazole	74	$ 108
3-11	Pyraclostrobin	80	$ 108
3-12	Silthiofam	85	$ 54
3-13	Simeconazole	87	$ 36
3-14	Tricyclopyricarb	88	$ 36
3-15	Trifloxystrobin	90	$ 126
3-16	Zoxamide	96	$ 72

successfully!

CheckOut

List of tables:

Table No.	Table Title
Table 1.1-1	Patent situation of benzobicyclon in some countries/regions, as of Oct. 2012
Table 1.2-1	Patent situation of dimethenamid-P in some countries/regions, as of Oct. 2012
Table 1.2-2	Registration situation of dimethenamid-P in Australia, as of Oct. 2012
Table 1.2-3	Registration situation of dimethenamid-P in Belgium, as of Oct. 2012
Table 1.2-4	Registration situation of dimethenamid-P in Netherlands, as of Oct. 2012
Table 1.2-5	Registration situation of dimethenamid-P in Switzerland, as of Oct. 2012
Table 1.3-1	Patent situation of fentrazamide in some countries/regions, as of Oct. 2012
Table 1.4-1	Patent situation of foramsulfuron in some countries/regions, as of Oct. 2012
Table 1.4-2	Registration situation of foramsulfuron in Argentina, as of Oct. 2012
Table 1.4-3	Registration situation of foramsulfuron in Australia, as of Oct. 2012
Table 1.4-4	Registration situation of foramsulfuron in Chile, as of Oct. 2012
Table 1.4-5	Registration situation of foramsulfuron in Netherlands, as of Oct. 2012
Table 1.4-6	Registration situation of foramsulfuron in Paraguay, as of Oct. 2012
Table 1.4-7	Registration situation of foramsulfuron in Switzerland, as of Oct. 2012
Table 1.4-8	Registration situation of foramsulfuron in Uruguay, as of Oct. 2012
Table 1.5-1	Patent situation of mesosulfuron-methyl in some countries/regions, as of Oct. 2012
Table 1.5-2	Registration situation of mesosulfuron-methyl in Australia, as of Oct. 2012
Table 1.5-3	Registration situation of mesosulfuron-methyl in Belgium, as of Oct. 2012
Table 1.5-4	Registration situation of mesosulfuron-methyl in Chile, as of Oct. 2012
Table 1.5-5	Registration situation of mesosulfuron-methyl in China, as of Oct. 2012
Table 1.5-6	Registration situation of mesosulfuron-methyl in Netherlands, as of Oct. 2012
Table 1.5-7	Registration situation of mesosulfuron-methyl in South Africa, as of Oct. 2012
Table 1.5-8	Registration situation of mesosulfuron-methyl in Switzerland, as of Oct. 2012
Table 1.6-1	Patent situation of monosulfuron in some countries/regions, as of Oct. 2012
Table 1.6-2	Registration situation of monosulfuron in China, as of Oct. 2012
Table 1.7-1	Patent situation of oxaziclomefone in some countries/regions, as of Oct. 2012
Table 1.7-2	Registration situation of oxaziclomefone in China, as of Oct. 2012
Table 1.8-1	Patent situation of pyribenzoxim in some countries/regions, as of Oct. 2012
Table 1.8-2	Registration situation of pyribenzoxim in China, as of Oct. 2012
Table 2.1-1	Patent situation of bifenazate in some countries/regions, as of Oct. 2012
Table 2.1-2	Registration situation of bifenazate in Argentina, as of Oct. 2012
Table 2.1-3	Registration situation of bifenazate in Australia, as of Oct. 2012
Table 2.1-4	Registration situation of bifenazate in Belgium, as of Oct. 2012
Table 2.1-5	Registration situation of bifenazate in Chile, as of Oct. 2012
Table 2.1-6	Registration situation of bifenazate in China, as of Oct. 2012
Table 2.1-7	Registration situation of bifenazate in Netherlands, as of Oct. 2012
Table 2.1-8	Registration situation of bifenazate in Switzerland, as of Oct. 2012
Table 2.2-1	Patent situation of diflovidazin in some countries/regions, as of Oct. 2012
Table 2.3-1	Patent situation of dinotefuran in some countries/regions, as of Oct. 2012
Table 2.4-1	Patent situation of flonicamid in some countries/regions, as of Oct. 2012
Table 2.4-2	Registration situation of flonicamid in Argentina, as of Oct. 2012
Table 2.4-3	Registration situation of flonicamid in Belgium, as of Oct. 2012
Table 2.4-4	Registration situation of flonicamid in Brazil, as of Oct. 2012
Table 2.4-5	Registration situation of flonicamid in China, as of Oct. 2012
Table 2.4-6	Registration situation of flonicamid in Netherlands, as of Oct. 2012
Table 2.4-7	Registration situation of flonicamid in Switzerland, as of Oct. 2012
Table 2.5-1	Patent situation of metaflumizone in some countries/regions, as of Oct. 2012
Table 2.5-2	Registration situation of metaflumizone in Argentina, as of Oct. 2012
Table 2.6-1	Patent situation methoxyfenozide in some countries/regions, as of Oct. 2012
Table 2.6-2	Registration situation of methoxyfenozide in Argentina, as of Oct. 2012
Table 2.6-3	Registration situation of methoxyfenozide in Australia, as of Oct. 2012
Table 2.6-4	Registration situation of methoxyfenozide in Belgium, as of Oct. 2012
Table 2.6-5	Registration situation of methoxyfenozide in Brazil, as of Oct. 2012
Table 2.6-6	Registration situation of methoxyfenozide in China, as of Oct. 2012
Table 2.6-7	Registration situation of methoxyfenozide in Switzerland, as of Oct. 2012
Table 2.6-8	Registration situation of methoxyfenozide in Uruguay, as of Oct. 2012
Table 2.7-1	Patent situation of profurite-aminium in some countries/regions, as of Oct. 2012
Table 2.7-2	Registration situation of profurite-aminium in China, as of Oct. 2012
Table 2.8-1	Patent situation of pyridalyl in some countries/regions, as of Oct. 2012
Table 2.9-1	Patent situation of spirodiclofen in some countries/regions, as of Oct. 2012
Table 2.9-2	Registration situation of spirodiclofen in Argentina, as of Oct. 2012
Table 2.9-3	Registration situation of spirodiclofen in Belgium, as of Oct. 2012
Table 2.9-4	Registration situation of spirodiclofen in Brazil, as of Oct. 2012
Table 2.9-5	Registration situation of spirodiclofen in Chile, as of Oct. 2012
Table 2.9-6	Registration situation of spirodiclofen in China, as of Oct. 2012
Table 2.9-7	Registration situation of spirodiclofen in Netherlands, as of Oct. 2012
Table 2.9-8	Registration situation of spirodiclofen in Switzerland, as of Oct. 2012
Table 2.10-1	Patent situation of thiamethoxam in some countries/regions, as of Oct. 2012
Table 2.10-2	Registration situation of thiamethoxam in Argentina, as of Oct. 2012
Table 2.10-3	Registration situation of thiamethoxam in Australia, as of Oct. 2012
Table 2.10-4	Registration situation of thiamethoxam in Belgium, as of Oct. 2012
Table 2.10-5	Registration situation of thiamethoxam in Brazil, as of Oct. 2012
Table 2.10-6	Registration situation of thiamethoxam in Chile, as of Oct. 2012
Table 2.10-7	Registration situation of thiamethoxam in China, as of Oct. 2012
Table 2.10-8	Registration situation of thiamethoxam in Netherlands, as of Oct. 2012
Table 2.10-9	Registration situation of thiamethoxam in Paraguay, as of Oct. 2012
Table 2.10-10	Registration situation of thiamethoxam in South Africa, as of Oct. 2012
Table 2.10-11	Registration situation of thiamethoxam in Switzerland, as of Oct. 2012
Table 2.10-12	Registration situation of thiamethoxam in Uruguay, as of Oct. 2012
Table 2.11-1	Patent situation of xiaochongthion in some countries/regions, as of Oct. 2012
Table 2.11-2	Registration situation of xiaochongthion in China, as of Oct. 2012
Table 3.1-1	Patent situation of benthiavalicarb-isopropyl in some countries/regions, as of Oct. 2012
Table 3.1-2	Registration situation of benthiavalicarb-isopropyl in Belgium, as of Oct. 2012
Table 3.1-3	Registration situation of benthiavalicarb-isopropyl in Switzerland, as of Oct. 2012
Table 3.2-1	Patent situation of boscalid in some countries/regions, as of Oct. 2012
Table 3.2-2	Registration situation of boscalid in Argentina, as of Oct. 2012
Table 3.2-3	Registration situation of boscalid in Australia, as of Oct. 2012
Table 3.2-4	Registration situation of boscalid in Belgium, as of Oct. 2012
Table 3.2-5	Registration situation of boscalid in Brazil, as of Oct. 2012
Table 3.2-6	Registration situation of boscalid in Chile, as of Oct. 2012
Table 3.2-7	Registration situation of boscalid in China, as of Oct. 2012
Table 3.2-8	Registration situation of boscalid in Netherlands, as of Oct. 2012
Table 3.2-9	Registration situation of boscalid in South Africa, as of Oct. 2012
Table 3.2-10	Registration situation of boscalid in Switzerland, as of Oct. 2012
Table 3.2-11	Registration situation of boscalid in Uruguay, as of Oct. 2012
Table 3.3-1	Patent situation of cyflufenamid in some countries/regions, as of Oct. 2012
Table 3.3-2	Registration situation of cyflufenamid in Belgium, as of Oct. 2012
Table 3.3-3	Registration situation of cyflufenamid in Netherlands, as of Oct. 2012
Table 3.3-4	Registration situation of cyflufenamid in Switzerland, as of Oct. 2012
Table 3.4-1	Patent situation of ethaboxam in some countries/regions, as of Oct. 2012
Table 3.5-1	Patent situation of flumorph in some countries/regions, as of Oct. 2012
Table 3.5-2	Registration situation of flumorph in China, as of Oct. 2012
Table 3.6-1	Patent situation of ningnanmycin in some countries/regions, as of Oct. 2012
Table 3.6-2	Registration situation of ningnanmycin in China, as of Oct. 2012
Table 3.7-1	Patent situation of orysastrobin in some countries/regions, as of Oct. 2012
Table 3.8-1	Patent situation of penthiopyrad in some countries/regions, as of Oct. 2012
Table 3.9-1	Patent situation of proquinazid in some countries/regions, as of Oct. 2012
Table 3.9-2	Registration situation of proquinazid in Switzerland, as of Oct. 2012
Table 3.10-1	Patent situation of prothioconazole in some countries/regions, as of Oct. 2012
Table 3.10-2	Registration situation of prothioconazole in Argentina, as of Oct. 2012
Table 3.10-3	Registration situation of prothioconazole in Australia, as of Oct. 2012
Table 3.10-4	Registration situation of prothioconazole in Belgium, as of Oct. 2012
Table 3.10-5	Registration situation of prothioconazole in Brazil, as of Oct. 2012
Table 3.10-6	Registration situation of prothioconazole in Chile, as of Oct. 2012
Table 3.10-7	Registration situation of prothioconazole in Netherlands, as of Oct. 2012
Table 3.10-8	Registration situation of prothioconazole in Switzerland, as of Oct. 2012
Table 3.11-1	Patent situation of pyraclostrobin in some countries/regions, as of Oct. 2012
Table 3.11-2	Registration situation of pyraclostrobin in Argentina, as of Oct. 2012
Table 3.11-3	Registration situation of pyraclostrobin in Australia, as of Oct. 2012
Table 3.11-4	Registration situation of pyraclostrobin in Belgium, as of Oct. 2012
Table 3.11-5	Registration situation of pyraclostrobin in Brazil, as of Oct. 2012
Table 3.11-6	Registration situation of pyraclostrobin in Chile, as of Oct. 2012
Table 3.11-7	Registration situation of pyraclostrobin in China, as of Oct. 2012
Table 3.11-8	Registration situation of pyraclostrobin in Paraguay, as of Oct. 2012
Table 3.11-9	Registration situation of pyraclostrobin in Netherlands, as of Oct. 2012
Table 3.11-10	Registration situation of pyraclostrobin in Switzerland, as of Oct. 2012
Table 3.12-1	Patent situation of silthiofam in some countries/regions, as of Oct. 2012
Table 3.12-2	Registration situation of silthiofam in Belgium, as of Oct. 2012
Table 3.12-3	Registration situation of silthiofam in Chile, as of Oct. 2012
Table 3.12-4	Registration situation of silthiofam in China, as of Oct. 2012
Table 3.12-5	Registration situation of silthiofam in Netherlands, as of Oct. 2012
Table 3.12-6	Registration situation of silthiofam in South Africa, as of Oct. 2012
Table 3.13-1	Patent situation of simeconazole in some countries/regions, as of Oct. 2012
Table 3.14-1	Patent situation of tricyclopyricarb in some countries/regions, as of Oct. 2012
Table 3.14-2	Registration situation of tricyclopyricarb in China, as of Oct. 2012
Table 3.15-1	Patent situation of trifloxystrobin in some countries/regions, as of Oct. 2012
Table 3.15-2	Registration situation of trifloxystrobin in Argentina, as of Oct. 2012
Table 3.15-3	Registration situation of trifloxystrobin in Australia, as of Oct. 2012
Table 3.15-4	Registration situation of trifloxystrobin in Belgium, as of Oct. 2012
Table 3.15-5	Registration situation of trifloxystrobin in Brazil, as of Oct. 2012
Table 3.15-6	Registration situation of trifloxystrobin in Chile, as of Oct. 2012
Table 3.15-7	Registration situation of trifloxystrobin in China, as of Oct. 2012
Table 3.15-8	Registration situation of trifloxystrobin in Netherlands, as of Oct. 2012
Table 3.15-9	Registration situation of trifloxystrobin in Paraguay, as of Oct. 2012
Table 3.15-10	Registration situation of trifloxystrobin in South Africa, as of Oct. 2012
Table 3.15-11	Registration situation of trifloxystrobin in Switzerland, as of Oct. 2012
Table 3.15-12	Registration situation of trifloxystrobin in Uruguay, as of Oct. 2012
Table 3.16-1	Patent situation of zoxamide in some countries/regions, as of Oct. 2012
Table 3.16-2	Registration situation of zoxamide in Argentina, as of Oct. 2012
Table 3.16-3	Registration situation of zoxamide in Brazil, as of Oct. 2012
Table 3.16-4	Registration situation of zoxamide in Netherlands, as of Oct. 2012
Table 3.16-5	Registration situation of zoxamide in South Africa, as of Oct. 2012
Table 3.16-6	Registration situation of zoxamide in Switzerland, as of Oct. 2012

List of figures:

Figure No.	Figure Title
Figure 1.1-1	Chemical structure of benzobicyclon
Figure 1.1-2	Synthesis route of benzobicyclon
Figure 1.2-1	Chemical structure of dimethenamid-P
Figure 1.3-1	Chemical structure of fentrazamide
Figure 1.3-2	Synthesis route A of fentrazamide
Figure 1.3-3	Synthesis route B of fentrazamide
Figure 1.3-4	Synthesis route C of fentrazamide
Figure 1.4-1	Chemical structure of foramsulfuron
Figure 1.4-2	Synthesis route of foramsulfuron
Figure 1.5-1	Chemical structure of mesosulfuron-methyl
Figure 1.5-2	Synthesis route of mesosulfuron-methyl
Figure 1.6-1	Chemical structure of monosulfuron
Figure 1.7-1	Chemical structure of oxaziclomefone
Figure 1.7-2	Synthesis route of oxaziclomefone
Figure 1.8-1	Chemical structure of pyribenzoxim
Figure 1.8-2	Synthesis route of pyribenzoxim
Figure 2.1-1	Chemical structure of bifenazate
Figure 2.1-2	Synthesis route A of bifenazate
Figure 2.1-3	Synthesis route B of bifenazate
Figure 2.1-4	Synthesis route C of bifenazate
Figure 2.1-5	Synthesis route D of bifenazate
Figure 2.2-1	Chemical structure of diflovidazin
Figure 2.2-2	Synthesis route of diflovidazin
Figure 2.3-1	Chemical structure of dinotefuran
Figure 2.3-2	Synthesis route A of dinotefuran
Figure 2.3-3	Synthesis route B of dinotefuran
Figure 2.3-4	Synthesis route C of dinotefuran
Figure 2.3-5	Synthesis route D of dinotefuran
Figure 2.3-6	Synthesis route E of dinotefuran
Figure 2.4-1	Chemical structure of flonicamid
Figure 2.4-2	Synthesis route A of flonicamid
Figure 2.4-3	Synthesis route B of flonicamid
Figure 2.5-1	Chemical structure of metaflumizone
Figure 2.5-2	Synthesis route of metaflumizone
Figure 2.6-1	Chemical structure of methoxyfenozide
Figure 2.6-2	Synthesis route A of methoxyfenozide
Figure 2.6-3	Synthesis route B of methoxyfenozide
Figure 2.6-4	Synthesis route C of methoxyfenozide
Figure 2.7-1	Chemical structure of profurite-aminium
Figure 2.8-1	Chemical structure of pyridalyl
Figure 2.8-2	Synthesis route A of pyridalyl
Figure 2.8-3	Synthesis route B of pyridalyl
Figure 2.8-4	Synthesis route C of pyridalyl
Figure 2.9-1	Chemical structure of spirodiclofen
Figure 2.9-2	Synthesis route A of spirodiclofen
Figure 2.9-3	Synthesis route B of spirodiclofen
Figure 2.10-1	Chemical structure of thiamethoxam
Figure 2.10-2	Synthesis route A of thiamethoxam
Figure 2.10-3	Synthesis route B of thiamethoxam
Figure 2.10-4	Synthesis route C of thiamethoxam
Figure 2.10-5	Synthesis route D of thiamethoxam
Figure 2.11-1	Chemical structure of xiaochongthion
Figure 2.11-2	Synthesis route of xiaochongthion
Figure 3.1-1	Chemical structure of benthiavalicarb-isopropyl
Figure 3.1-2	Synthesis route of benthiavalicarb-isopropyl
Figure 3.2-1	Chemical structure of boscalid
Figure 3.2-2	Synthesis route A of boscalid
Figure 3.2-3	Synthesis route B of boscalid
Figure 3.3-1	Chemical structure of cyflufenamid
Figure 3.3-2	Synthesis route of cyflufenamid
Figure 3.4-1	Chemical structure of ethaboxam
Figure 3.4-2	Synthesis route of ethaboxam
Figure 3.5-1	Chemical structure of flumorph
Figure 3.5-2	Synthesis route of flumorph
Figure 3.6-1	Chemical structure of ningnanmycin
Figure 3.7-1	Chemical structure of orysastrobin
Figure 3.7-2	Synthesis route A of orysastrobin
Figure 3.7-3	Synthesis route B of orysastrobin
Figure 3.7-4	Synthesis route C of orysastrobin
Figure 3.8-1	Chemical structure of penthiopyrad
Figure 3.8-2	Synthesis route A of penthiopyrad
Figure 3.8-3	Synthesis route B of penthiopyrad
Figure 3.9-1	Chemical structure of proquinazid
Figure 3.10-1	Chemical structure of prothioconazole
Figure 3.10-2	Synthesis route A of prothioconazole
Figure 3.10-3	Synthesis route B of prothioconazole
Figure 3.10-4	Synthesis route C of prothioconazole
Figure 3.10-5	Synthesis route D of prothioconazole
Figure 3.11-1	Chemical structure of pyraclostrobin
Figure 3.11-2	Synthesis route A of pyraclostrobin
Figure 3.11-3	Synthesis route B of pyraclostrobin
Figure 3.12-1	Chemical structure of silthiofam
Figure 3.12-2	Synthesis route of silthiofam
Figure 3.13-1	Chemical structure of simeconazole
Figure 3.13-2	Synthesis route of simeconazole
Figure 3.14-1	Chemical structure of tricyclopyricarb
Figure 3.14-2	Synthesis route of tricyclopyricarb
Figure 3.15-1	Chemical structure of trifloxystrobin
Figure 3.15-2	Synthesis route A of trifloxystrobin
Figure 3.15-3	Synthesis route B of trifloxystrobin
Figure 3.15-4	Synthesis route C of trifloxystrobin
Figure 3.16-1	Chemical structure of zoxamide
Figure 3.16-2	Synthesis route A of zoxamide
Figure 3.16-3	Synthesis route B of zoxamide

CCM Customized Service on Market Research

Do you want Import & Export Analysis, Financial Data, Cost Analysis, Supply Chain Research etc. ? We will customize the specific research for you, in case the services listed above does not meet your precise requirements. Our product and industry research in China’s agriculture, chemicals, food & ingredients and life science markets will comprehensively cover the business information, which is able to help you arrive at strategic and profitable business decisions.

Please directly contact econtact@cnchemicals.com to specify your Market Research Requirement

SAMPLE DOWNLOAD

In order to provide you with access to all the free content on this site, we would like you to tell us who you are.
Please enter the following - you will only have to do this once. Or if you already have an account, please sign in here.

* Name
* Your E-mail address
* Your phone number
Your company
* Your industry

Recommend Report

Need some help to find your information ?

Search Report

Recommend Newsletter

Related market data

Related product

Related research

Guide of Coming Off-patent Agrochemical Active Ingredients

Single user license: USD 1,800
Corporate license: USD 4,500

All the prices on this website exclude VAT.

Description:

Main contents:

List of tables:

List of figures:

CCM Customized Service on Market Research

SAMPLE DOWNLOAD

My Products (0 items)

Login/Register

Recommend Report

Need some help to find your information ?

Search Report

Recommend Newsletter

Related market data

Related product

Related research

Guide of Coming Off-patent Agrochemical Active Ingredients

Single user license: USD 1,800 Corporate license: USD 4,500 All the prices on this website exclude VAT.

Description:

Main contents:

List of tables:

List of figures:

CCM Customized Service on Market Research

SAMPLE DOWNLOAD

Single user license: USD 1,800
Corporate license: USD 4,500

All the prices on this website exclude VAT.